CTO-PCI Technology for Heart Health in Egypt
The article from the Egypt Healthcare Authority (EHA) discusses the successful implementation and benefits of using CTO-PCI (Chronic Total Occlusion Percutaneous Coronary Intervention) technology to treat chronic coronary artery occlusion in Egypt. Here are some key points to consider:
- Success of Procedures: The EHA reported the successful treatment of three elderly patients (all over 60 years old) using CTO-PCI technology with micro-catheters and specialised wires at the International Medical Complex in Luxor. The procedures achieved a 100% success rate.
- Cost and Universal Health Coverage: The cost of CTO-PCI procedures outside the universal health coverage system exceeds 500,000 Egyptian pounds. However, under the universal health insurance system, patients contribute no more than 400 EGP.
- Medical Team and Expertise: The procedures were conducted by a highly skilled team of medical consultants, including top professors, cardiologists, and specialised nursing and technical staff. Key team members included Dr. Tarek Rashid, Head of the Scientific Committee for Cardiology, and Dr. Zein El-Abidin Abdel-Latif, Head of the Cardiology and Catheterization Department.
- Commitment to Innovation: The EHA emphasised its commitment to innovation and continuous development, adopting the latest global medical advances and introducing cutting-edge technologies across all medical specialties, particularly in cardiology.
- Patient Benefits: The patients treated were suffering from angina and severe pain due to coronary artery occlusion. The use of CTO-PCI technology significantly improved their quality of life.
- Healthcare Model: The EHA aims to provide a modern healthcare model in Egypt by ensuring access to the latest global medical advancements and maintaining a team of expert consultants.
This initiative reflects the Authority‘s dedication to providing innovative medical technologies and achieving high-quality care for patients under the universal health insurance system.
Recent Posts
Omaveloxolone Appropriate Utilization Consensus Framework for Friedreich Ataxia
The omaveloxolone appropriate utilization consensus delivers a tightly controlled framework for using Skyclarys in Friedreich’s ataxia, restricting initiation and discontinuation decisions to two specialized Dutch centers. By combining validated functional scales with strict safety thresholds and...
Conditional Adoption Pathways for Endometriosis Diagnostics
The introduction of conditional adoption pathways for endometriosis offers a structured route to faster diagnosis for the millions of women facing four-to-ten-year delays within the NHS. N...
Biologic Dispensing Implementation Gaps Challenge Patient Access to Care
Biologic dispensing implementation gaps are undermining equitable access to advanced therapies for inflammatory bowel disease across Portugal’s public hospitals. Despite clear legislative changes, institutions continue to reject prescriptions for biologics written by private specialists, forcing ...